Lilly takes AI-selected Olumiant into phase 3 for COVID-19

Eli Lilly has enrolled the first patient into a phase 3 trial that is seeking to repurpose arthritis drug Olumiant as a treatment for people with COVID-19.

Eyeing Dupixent’s territory, Leo Pharma files tralokinumab i...

The EMA has started a review of Leo Pharma’s interleukin-13 inhibitor tralokinumab as an antibody therapy for atopic dermatitis, a category that is currently dominated by Sanof

Lilly announces CNS tie-up with UK biotech Evox Therapeutics

Eli Lilly has announced a central nervous system research tie-up with UK biotech Evox Therapeutics, which focuses on drug engineering using vesicles to deliver drugs to targets. 

FDA clears Lilly’s Retevmo for RET-positive lung, thyroid ca...

Eli Lilly now has a second approved drug from its takeover of Loxo Oncology last year after getting the go-ahead from the FDA for RET inhibitor Retevmo.

Lilly raises 2020 earnings forecast on pandemic stockpiling

AZ, Lilly join efforts to develop drugs for COVID-19